Drug Trial Radar · NCT03589326
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
Last checked: Nov 20, 2026Latest source record: Nov 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
245
Actual
Start
Oct 4, 2018
Primary completion
Aug 12, 2022
Study completion Jul 31, 2027
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Jul 17, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, adults with newly-diagnosed Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) will receive first-line therapy of ponatinib or imatinib. The main aim of this study is to compare the number of participants on each treatment that show no signs of disease. Participants will take tablets of either ponatinib or imatinib at the same time each day combined with reduced-intensity chemotherapy for up to 20 months. Then, they will continue with single-agent therapy (ponatinib or imatinib) until they meet the discontinuation criteria from the study.
Conditions
- Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
Interventions
PonatinibDrug
Ponatinib Tablets.
ImatinibDrug
Imatinib Tablets.
VincristineDrug
Vincristine IV injection.
DexamethasoneDrug
Dexamethasone Tablets.
CytarabineDrug
Cytarabine IV infusion.
MethotrexateDrug
Methotrexate IV infusion.
PrednisoneDrug
Prednisone Tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Minimal Residual Disease (MRD)-Negative Complete Remission (CR) at The End of Induction PhaseTime frame: From Cycle 1 through Cycle 3 (approximately 3 months) (Cycle length = 28 days)
Locations
92 sites in 20 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
City of Hope - Duarte
Duarte, California
University of California Los Angeles
Los Angeles, California
Augusta University Georgia Cancer Center
Augusta, Georgia
Indiana University
Indianapolis, Indiana
Indiana Blood & Marrow Transplantation
Indianapolis, Indiana
University of Kansas Medical Center Research Institute
Kansas City, Kansas
University of Maryland Medical Center
Baltimore, Maryland
Hackensack University Medical Center
Hackensack, New Jersey
Roswell Park Cancer Institute
Buffalo, New York
Monter Cancer Center
New Hyde Park, New York
Stony Brook University Medical Center
Stony Brook, New York
Oregon Health and Science University
Portland, Oregon
The University of Texas MD Anderson Cancer Center
Houston, Texas
Methodist Hospital
San Antonio, Texas
Sanatorio Allende
Córdoba, Argentina
Hospital Privado Centro Medico de Cordoba
Córdoba, Argentina
Royal North Shore Hospital
Saint Leonards, New South Wales, Australia
Box Hill Hospital
Box Hill, Victoria, Australia
Monash Medical Centre
Clayton, Victoria, Australia
Universitaetsklinik Fuer Innere Medizin I
Vienna, Austria
Hanusch Krankenhaus Wiener Gebietskrankenkasse
Vienna, State of Vienna, Austria
Ordensklinikum Linz Elisabethinen
Linz, Upper Austria, Austria
HEMORIO Instituto Estadual de Hematologia Arthur Siqueira de Cavalcanti
Rio de Janeiro, Brazil
Instituto do Cancer do Estado de Sao Paulo
São Paulo, Brazil
Fundacao Antonio Prudente - A.C.Camargo Cancer Center
São Paulo, Brazil
Hospital Sao Rafael-Monte Tabor
Salvador, Estado de Bahia, Brazil
Hospital Erasto Gaertner
Curitiba, Paraná, Brazil
Hospital da Cidade
Passo Fundo, Rio Grande do Sul, Brazil
Hospital de Clinicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Hemocentro Campinas Unicamp
Campinas, São Paulo, Brazil
Fundacao Doutor Amaral Carvalho
Jaú, São Paulo, Brazil
Hospital das Clinicas da Faculdade de Medicina da Riberao Preto da Universidade de Sao Paulo
Ribeirão Preto, São Paulo, Brazil
University Multiprofile Hospital for Active Treatment Saint Ivan Rilski
Sofia, Sofia, Bulgaria
855 West 12th Avenue
Vancouver, British Columbia, Canada
The Ottawa Hospital
Ottawa, Ontario, Canada
Hopital Charles-LeMoyne
Greenfield Park, Quebec, Canada
Hopital Maisonneuve-Rosemont
Montreal, Quebec, Canada
Institute of Hematology & Blood Diseases Hospital of CAMS & PUMC
Tianjin, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Showing 40 of 92 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.